ClinicalTrials.gg

Program

CB03-154

A development code. Also written as “Test drug CB03-154 5mg group”, “Test drug CB03-154 10mg group” and “Test drug CB03-154 20mg group”.

Its studies are mostly in Epilepsies, Partial · Amyotrophic Lateral Sclerosis, led by Shanghai Zhimeng Biopharma.

Furthest: phase 3, since Jul 11, 20255 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Zhimeng Biopharma53 open or runningphase 3since Jul 11, 2025Aug 8, 2022Sep 2027phase 2 · NCT06612775

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2022First studies: 2 phase 1 studies in Healthy VolunteersFirst studyNCT05499260, NCT05502549
  2. Sep 19, 2024Phase 2 study in Epilepsies, PartialNCT06612775 · 180 planned · Australia
  3. Jul 11, 2025Phase 3 study in Amyotrophic Lateral SclerosisNCT07082192 · 240 planned · China
  4. Nov 16, 2025Phase 2 study in Epilepsies, PartialNCT07238868 · 144 planned · Australia

Ahead

  1. Sep 2027Primary completion: phase 2 study in Epilepsies, PartialNCT06612775
  2. Sep 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07082192
  3. Jan 2029Primary completion: phase 2 study in Epilepsies, PartialNCT07238868

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07238868Epilepsies, Partial · Australia2RecruitingJan 2029144
NCT07082192Amyotrophic Lateral Sclerosis · China3RecruitingSep 30, 2027240
NCT06612775Epilepsies, Partial · Australia2RecruitingSep 2027180
NCT05502549Healthy Volunteers · Australia1CompletedNov 9, 202356
NCT05499260Healthy Volunteers · United States1UNKNOWNMar 2, 202370

How it is read

Names in the registry

  • “CB03-154”, 3 entries
  • “Test drug CB03-154 5mg group”, 2 entries
  • “Test drug CB03-154 10mg group”, 2 entries
  • “Test drug CB03-154 20mg group”, 1 entry
  • “Test drug CB03-154 15mg group”, 1 entry

Codes read as this program: CB03154.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.